RxNorm 477485
natalizumab 20 MG/ML
RxNorm Semantic Concepts
RxNorm semantic concepts for the RxCUI 477485 unique identifier include: natalizumab 20 MG/ML (2181098).
RxNorm Atom ID: 2181098 - Semantic Clinical Drug Component
natalizumab 20 MG/ML
- RXCUI:
- 477485 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 2181098 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
- Concept Description:
- natalizumab 20 MG/ML - Description of concept identifier
- Term Type (TTY):
- SCDC - Term type in source with name and description
- Term Type Name:
- Semantic Clinical Drug Component - Name of term type in source
- Term Type Description:
- Ingredient + Strength - Description of term type in source
- Code:
- 477485 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- 4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
RxNorm Atom 2181098 Attributes
| Property | Value | Explanation |
|---|---|---|
| RXN BOSS STRENGTH DENOM UNIT | ML | RXN Boss Strength Denom Unit |
| RXN BOSS STRENGTH DENOM VALUE | 1 | RXN Boss Strength Denom Value |
| RXN BOSS STRENGTH NUM UNIT | MG | RXN Boss Strength Num Unit |
| RXN BOSS STRENGTH NUM VALUE | 20 | RXN Boss Strength Num Value |
| RXN STRENGTH | 20 MG/ML | Strength plus unit of SCDC |
* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Patient Education
Natalizumab Injection
Natalizumab is used to prevent episodes of symptoms and slow the worsening of disability in adults who have relapsing forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control), including: clinically isolated syndrome (CIS; first nerve symptom episode that lasts at least 24 hours), relapsing-remitting disease (course of disease where symptoms flare up from time to time), active secondary progressive disease (later stage of disease with continuous worsening of symptoms.) Natalizumab is also used to treat and prevent episodes of symptoms in adults who have Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) who have not been helped by other medications or who cannot take other medications. Natalizumab is in a class of medications called monoclonal antibodies. It works by stopping certain cells of the immune system from reaching the brain and spinal cord or digestive tract and causing damage.
[Learn More]
* Please review the disclaimer below.